2008

Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer

Mona Mostafa Mohamed
Dora Cavallo-Medved
University of Windsor
Bonnie F. Sloane

Follow this and additional works at: https://scholar.uwindsor.ca/biologypub

Part of the Biology Commons

Recommended Citation
https://scholar.uwindsor.ca/biologypub/25
Short Communication

Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer

Mona Mostafa Mohamed1,*, Dora Cavallo-Medved2,3 and Bonnie F. Sloane2,3
1 Department of Zoology, Faculty of Science, Cairo University, 12613 Cairo, Egypt
2 Department of Pharmacology, Wayne State University, Detroit, MI 48201, USA
3 Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
*Corresponding author
e-mail: monamos@link.net

Abstract

Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, and here, we examined in vitro the interactions between the human IBC cell line SUM149 and U937 human naive monocytes. We found an altered morphology, enhanced invasiveness and proteolytic activity of SUM149 cells when cultured with U937 cells or in U937-conditioned media (U937-CM). Increases in expression and activity of the cysteine protease cathepsin B and expression of caveolin-1 were also detected in SUM149 cells grown in U937-CM, thus suggesting a contribution of these proteins to the augmented invasion through and proteolysis of the extracellular matrix by the IBC cells. 

Keywords: cathepsin B; caveolin-1; co-culture; extracellular matrix; proteolysis.

Inflammatory breast cancer (IBC) is the most lethal form of primary breast cancer and disproportionately targets younger women. Although IBC accounts for up to 5% of all breast cancer cases in the United States, its incidence is significantly higher among African-American women (10.1%) and women of Northern African countries (1–10%) (Omar et al., 2003; Labidi et al., 2008). Surveillance Epidemiology and End Results (SEER) analysis revealed that the incidence of IBC increased approximately 2.5-fold between 1990 and 1997, whereas the incidence of non-inflammatory locally advanced breast cancer (LABC) decreased by approximately 2.5-fold (Hance et al., 2005). Despite multi-modal treatment protocols utilizing neoadjuvant chemotherapy, mastectomy followed by adjuvant chemotherapy and accelerated hyperfractionated radiation, the 3-year survival rate for patients with IBC is merely 40% as compared to 85% for non-IBC patients (Lerebours et al., 2005). Dismal survival rates for IBC patients are attributed to the rapid progression, significant lymph node involvement and distant metastasis of the disease at the time of diagnosis. Moreover, a palpable tumor mass is not usually present in IBC, thus making diagnosis challenging using conventional mammography or breast ultrasound (Cariati et al., 2005; Hance et al., 2005).

Clinically, IBC is a form of LABC that is of ductal cellular origin and has distinct features that include rapid onset, erythema, edema of the breast and a ‘peau d’orange’ appearance of the skin. IBC tumors are highly proliferative, angiogenic and invasive, particularly into dermal lymphatic vessels where they form tumor emboli (Van Laere et al., 2006). Lymphatic obstruction by these tumor emboli underlies the inflammatory nature of the disease (Giordano and Hortobagyi, 2003; Lerebours et al., 2005). While there are recent efforts to study IBC, the molecular and genetic nature of this disease remains poorly understood. A number of prognostic markers for IBC, including HER2/neu amplification/overexpression and lack of estrogen receptor, have been identified (Delaire et al., 1981). Overexpression of genes, such as epidermal growth factor receptor (egfr), rhoC and e-cadherin, and the loss of expression of genes, including icb (lost in inflammatory breast cancer) and wisp3 (Wnt-1-inducible secreted protein 3), highly correlate with IBC tumorigenesis (van Golen et al., 1999; Klee et al., 2005). Unfortunately, these markers do not distinguish IBC from non-IBC and fail to explain their distinct biology (Bieche et al., 2004).

Along with IBC cells, investigators are now profiling stromal cells associated with IBC. For example, fibroblasts associated with breast cancer can induce ‘genetic alterations’ related to poor prognosis of the disease (Radisky and Radisky, 2007). As well, monocytes that infiltrate into the breast tissue proliferate and differentiate into tumor-associated macrophages, a cell type for which a strong association has been made with poor prognosis of breast cancer (Leek et al., 1996). Advances in intravital imaging technology have provided new insights into how migration and invasion of breast cancer cells are regulated by elements of the local microenvironment, including the presence of macrophages (Condeelis and Pollard, 2006). For example, toll-like receptors, which are highly expressed by myelomonocytic cells, including circulating monocytes, macrophages and dendritic cells, in response to microbial or viral infections (Nagai et al., 2006), are also overexpressed in IBC patient tissue (Van Laere et al., 2005). These receptors are also upstream activators of NF-κB transcription, and in breast cancer NF-κB promotes invasion by increasing cell motility and migration (Huber et al., 2004). Thus, these data support our hypothesis that inflammatory cells, such as monocytes enhance IBC tumorigenesis, malignancy and lymphovascular invasion (Schoppmann et al., 2006).

Previously, we investigated the interactions between non-IBC cell lines (MDA-MB-231 and BT20) and naive or tumor-educated U937 human monocytes (Sameni et al.,...
2003; Mohamed and Sloane, unpublished data). In these studies, breast cancer cells were either co-cultured with naive or tumor-educated monocytes or treated with the conditioned media of these cells. These interactions result in increased proteolytic activity, extracellular matrix (ECM) degradation and invasiveness of the breast tumor cells. Moreover, using cytokine antibody arrays, we identified the major cytokines and proteases potentially involved in the cross-talk between these breast tumor cells and human monocytes (Mohamed and Sloane, unpublished data). Here, we studied the response of the human IBC cell line SUM149 to U937 human monocytes.

Using confocal microscopy, we assessed the morphology of SUM149 cells grown on a reconstituted basement membrane (rBM) and overlaid with 2% rBM, a method adapted from one used by Brugge and colleagues to analyze morphogenesis and oncogenesis of breast epithelial cells (Debnath et al., 2003). We found that SUM149 cells grown alone on rBM for 24 h formed spheroid-like structures (Figure 1A). When these cells were grown in co-culture with U937 (Figure 1B) or in media conditioned by U937 cells (U937-CM; Figure 1C), we observed in both cases a morphological change from spheroidal to branching-like structures. In addition, U937-CM enhanced the invasion of SUM149 cells through rBM-coated filters as compared to control media (Ham’s F-12 media plus 5% fetal bovine serum, FBS) (Figure 2). Our data suggest that secretions from U937 cells stimulate morphological changes in SUM149 cells and promote their invasion.

Since invasion of tumor cells is linked to degradation of ECM proteins, we examined the effects of monocytes on degradation of the ECM protein type IV collagen by SUM149 cells. In a live cell proteolysis assay that uses a collagenase assay, we found that U937 cells alone or in culture with U937 cells significantly increased the degradation of type IV collagen by SUM149 cells. These results suggest a role for U937 cells in promoting the invasive behavior of IBC cells.
Figure 4  Conditioned media from U937 cells increases the levels and activity of cathepsin B in SUM149 cells. To specifically see the effect of U937 from on the expression of cathepsin B in SUM149 without the influence of rBM, SUM149 cells were grown on plastic for 48 h in complete media alone (Ham’s F12 media with 5% FBS) (lane 1) or with U937-CM (lane 2), washed several times with phosphate buffered saline and incubated overnight in serum-free medium. Cells were solubilized in lysis buffer (250 mM sucrose, 25 mM MES pH 7.5, 1 mM EDTA, 0.1% Triton X-100 (Sigma)) and cell lysates were subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted with polyclonal antibodies against cathepsin B (Moin et al., 1992) and ß-actin (Sigma) as a loading control. Cathepsin B forms observed are the proenzyme (43/46 kDa), an intermediate form (38 kDa), single chain mature enzyme (31 kDa) and the heavy chain of double chain mature enzyme (25/26 kDa heavy chain) (A). Immunoblots are representative of at least three independent experiments. Cathepsin B activity in cell lysates was determined using a fluorogenic enzymatic assay that employs 100 µM Z-Arg-Arg-NH2Mec (Bachem, Torrance, CA, USA), which under the conditions of this assay is a selective substrate for cathepsin B (Linebaugh et al., 1999), in the presence and absence of 10 µM CA074 (Peptide Institute, Louisville, KY, USA), a highly selective inhibitor of cathepsin B (Linebaugh et al., 1999; Montaser et al., 2002). Cathepsin B activity in the cell lysates of SUM149 cells grown in complete media (white bar) and in U937-CM (black bars) is expressed as pmol/min/µg DNA (B). Pepsin (Roche, Indianapolis, IN, USA)–activated cathepsin B activity was also measured in the conditioned media of both SUM149 (positive control) and U937 cells using 100 µM Z-Arg-Arg substrate (Linebaugh et al., 1999) and expressed as pmol/min/µg DNA (C). The inset panel shows SUM149 (lane 1) and U937 (lane 2) conditioned media subjected to SDS-PAGE and immunoblotting using polyclonal cathepsin B antibody. Graphs are representative of at least three independent experiments and presented as mean±S.D. *Indicates a p-value <0.05, as determined by Student’s t-test. Intracellular immunostaining for cathepsin B (green) was performed on SUM149 cells grown on glass coverslips in complete media (Ham’s F12 medium with 5% FBS) (D) or in U937-CM (E). Cells were incubated in the presence of saponin (Sigma) with a primary polyclonal antibody against cathepsin B followed by FITC-conjugated affinity-purified donkey anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, USA) plus 5% normal donkey serum (Cavallo-Medved et al., 2005). Confocal microscopy was performed in MIRL with a Zeiss LSM 510 META NLO microscope (Carl Zeiss) using a 63X lens under oil immersion. On glass coverslips, IBC cells form a monolayer, thus differing in morphology from those illustrated in Figure 1 where they are grown in a three-dimensional rBM culture. These images are representative of three experiments. Nuclei were stained with DAPI (blue). Bars, 10 µm.

dye-quenched fluorescent (DQ)-collagen IV substrate, the most abundant collagen type found in basement membrane, mixed with rBM (Sameni et al., 2003), we found increased DQ-collagen IV degradation (observed as green fluorescence) when SUM149 cells were co-cultured with U937 cells as compared to when they were grown alone (Figure 3). The increase in DQ-collagen IV degradation correlates with the branched morphology of SUM149 cells induced by co-culture with U937 cells and the enhanced invasiveness of SUM149 cells in response to U937-CM.

As a first step in identifying which enzymes are involved in ECM degradation, we examined the expression and activity of a lysosomal cysteine protease, cathepsin B, in SUM149 cells. Cathepsin B is involved in various steps of tumor progression, including digestion of adhesion molecules, degradation of extracellular matrix, motility, angiogenesis, invasion and metastasis (Ren and Sloane, 1996; Mohamed and Sloane, 2006). Moreover, cathepsin B has been suggested to be a biological marker for breast tumors (Wulfkuhle et al., 2002) and has been implicated in breast tumor cell invasion (Lah et al., 2000; Premzl et al., 2003). In a recent study, a nanoparticle delivery system composed of poly(ε-caprolactone-coglycolide) nanoparticles, anti-cytokeratin monoclonal IgG and cystatin was used to penetrate
breast cancer cells and inhibit intracellular cathepsin B activity, respectively, thereby reducing the invasiveness of these tumor cells in vitro (Obermajer et al., 2007). Here, in immunoblotting and fluorogenic enzymatic assays (Linebaugh et al., 1999), we detected increases in cathepsin B expression and activity in SUM149 cells grown in U937-CM (Figure 4). In these experiments, SUM149 cells were grown on plastic to examine the direct effects of U937-CM (i.e., in the absence of rBM) on these cells. CA074, a highly selective cathepsin B inhibitor (Montaser et al., 2002), was used to verify cathepsin B activity detected in the enzymatic assay (Figure 4B). Moreover, both immunoblotting and enzymatic assays verified the absence of cathepsin B in U937-CM as compared to conditioned media of SUM149 cells (SUM149-CM) used as a positive control (Figure 4C). This indicated that the increase in cathepsin B expression and activity detected in SUM149 cells grown in U937-CM was not a result of uptake of cathepsin B secreted from U937 cells (Figure 4C). Thus, the upregulation in cathepsin B expression and activity in SUM149 cells would be consistent with this enzyme contributing to the increases in both ECM degradation and invasion by these cells. Furthermore, we analyzed subcellular distribution of cathepsin B in SUM149 grown in coverslips in the absence and presence of U937-CM (Figure 4D and E, respectively). Increased expression of cathepsin B, localized in vesicles in the perinuclear region, was detected in SUM149 grown in U937-CM (Figure 4E). Analyses of other proteases that may contribute to increases in ECM degradation and invasion are ongoing.

Caveolin-1, the structural protein of lipid raft caveolae, was initially reported to act as a breast tumor suppressor (Bouras et al., 2004); however, recent studies have classified caveolin-1 and -2 as biomarkers for the basal-like phenotype in the breast carcinoma subgroup (Sagara et al., 2004; Pinilla et al., 2006) that includes IBC (Perou et al., 2000). Upregulation of caveolin-1 has been observed in other malignancies, such as colon, prostate and pancreatic cancers (Yang et al., 1998; Fine et al., 2001; Suzuoki et al., 2002), particularly in the metastatic stage of the disease. In IBC cell lines and patient tumor tissues, overexpression of caveolin-1 and -2 correlates with increased expression of RhoC, implicating these proteins in the aggressive phenotype of IBC (Van den Eynden et al., 2006). We have previously suggested that caveolin-1 and caveolae contribute to tumor invasion by compartmentalizing several cell surface proteases involved in ECM degradation (Cavallo-Medved et al., 2005), and our ongoing studies using patient samples will elucidate the contribution of caveolae-associated proteases in the metastatic phenotype of IBC. We have identified cell surface cathepsin B associated with caveolae of human colorectal carcinoma cells (Cavallo-Medved et al., 2003). Moreover, we found that downregulation of caveolin-1 alters trafficking of cathepsin B to caveolae and decreases secretion of this enzyme, thereby reducing ECM degradation by and invasion of these cells (Cavallo-Medved et al., 2005). Here, we found that in SUM149 cells grown in U937-CM, caveolin-1 expression was significantly increased compared to control SUM149 cells (Figure 5). These results correlate with the overexpression of cathepsin B in SUM149 cells under these conditions and may suggest an increase in the association of cathepsin B with caveolae.

Our study supports the hypothesis that interaction of monocytes with IBC cells stimulates the invasiveness of IBC cells. We speculate that this is the result of enhanced cell surface activity of the cysteine protease cathepsin B in IBC cells. The increased invasion and proteolysis in the IBC cells are accompanied by: (i) increased expression and activity of cathepsin B, and (ii) increased expression of caveolin-1, caveolae being a site for localization of cathepsin B on the tumor cell surface.

Acknowledgments

We acknowledge with special gratitude the contributions of J. Doescu, M.B. Olive, D. Rudy and K. Moin to these studies. We also thank Dr. Stephen P. Ether, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA, for kindly providing us with the SUM149 cell line. The authors were supported by an Avon Foundation American Association for Cancer Research International Scholar Award in Breast Cancer Research (M.M.M.), an Avon grant #02-2007-049 (M.M.M., D.C.M., B.F.S.) and National Institutes of Health (NIH) grant CA 56586 (B.F.S.). Microscopy and Imaging Resources Laboratory is supported in part by National Institutes of Health Center Grants P30ES06639 and P30CA22453 and a Roadmap Grant U54RR020843.

References


Received December 14, 2007; accepted April 7, 2008